The European Commission has approved Boey® (trenibotulinumtoxinE) for temporary improvement of moderate to severe glabellar lines in adults, marking it as the first rapid-onset, short-duration botulinum neurotoxin serotype E available in Europe. Results can appear as soon as eight hours after treatment and typically last two to three weeks. Developed by Allergan Aesthetics, Boey® offers a new option for patients hesitant about long-lasting injectables, allowing a temporary preview of effects. Allergan plans to launch Boey® across Europe with healthcare professional training to support its use.
US stock futures point to a strong start with Dow Jones up 1.1%, S&P 500 up 0.9%, and Nasdaq up 1.5%, driven by a sharp 6.3% drop in oil prices following a pause in US-Iran military actions. Although no official ceasefire is declared, Iran has agreed...
AbbVie has earned a buy rating due to accelerating revenue and profit growth, supported by a reasonable valuation at 18 times forward P/E. The company offers a 2.7% forward dividend yield, outperforming its peers by 68%, and has maintained 12 consecu...
Genmab and AbbVie announced that the Phase 3 EPCORE DLBCL-1 trial evaluating epcoritamab, a bispecific antibody treatment for relapsed or refractory diffuse large B-cell lymphoma (DLBCL), did not meet its primary endpoint of overall survival (OS) in ...
